361 related articles for article (PubMed ID: 11236033)
21. [Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].
Guo MG; Jiang MH; Yang Q; Li YM; Cui ZF; Li LF; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1147-51. PubMed ID: 15387973
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
[TBL] [Abstract][Full Text] [Related]
23. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
[TBL] [Abstract][Full Text] [Related]
24. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.
Agus DB; Bunn PA; Franklin W; Garcia M; Ozols RF
Semin Oncol; 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100. PubMed ID: 11236029
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
26. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
[TBL] [Abstract][Full Text] [Related]
27. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC
Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
[TBL] [Abstract][Full Text] [Related]
28. Ongoing and planned adjuvant trials with trastuzumab.
Perez EA; Hortobagyi GN
Semin Oncol; 2000 Dec; 27(6 Suppl 11):26-32; discussion 92-100. PubMed ID: 11236024
[TBL] [Abstract][Full Text] [Related]
29. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
Mann M; Sheng H; Shao J; Williams CS; Pisacane PI; Sliwkowski MX; DuBois RN
Gastroenterology; 2001 Jun; 120(7):1713-9. PubMed ID: 11375952
[TBL] [Abstract][Full Text] [Related]
30. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
31. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab.
Biroccio A; D'Angelo C; Jansen B; Gleave ME; Zupi G
J Cell Physiol; 2005 Aug; 204(2):463-9. PubMed ID: 15685647
[TBL] [Abstract][Full Text] [Related]
32. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
Meric-Bernstam F; Hung MC
Clin Cancer Res; 2006 Nov; 12(21):6326-30. PubMed ID: 17085641
[TBL] [Abstract][Full Text] [Related]
33. HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity.
Hsu C; Huang CL; Hsu HC; Lee PH; Wang SJ; Cheng AL
Cancer; 2002 Jan; 94(2):415-20. PubMed ID: 11900227
[TBL] [Abstract][Full Text] [Related]
34. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
35. Targeting HER2: recent developments and future directions for breast cancer patients.
Wang SC; Zhang L; Hortobagyi GN; Hung MC
Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Dang CT; Dannenberg AJ; Subbaramaiah K; Dickler MN; Moasser MM; Seidman AD; D'Andrea GM; Theodoulou M; Panageas KS; Norton L; Hudis CA
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4062-7. PubMed ID: 15217939
[TBL] [Abstract][Full Text] [Related]
37. The HER receptor family: a rich target for therapeutic development.
Mass RD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):932-40. PubMed ID: 14967453
[TBL] [Abstract][Full Text] [Related]
38. Basic science of HER-2/neu: a review.
Hung MC; Lau YK
Semin Oncol; 1999 Aug; 26(4 Suppl 12):51-9. PubMed ID: 10482194
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
Menendez JA; Mehmi I; Lupu R
J Clin Oncol; 2006 Aug; 24(23):3735-46. PubMed ID: 16847284
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Giuliani R; Durbecq V; Di Leo A; Paesmans M; Larsimont D; Leroy JY; Borms M; Vindevoghel A; Jerusalem G; D'Hondt V; Dirix L; Canon JL; Richard V; Cocquyt V; Majois F; Reginster M; Demol J; Kains JP; Delree P; Keppens C; Sotiriou C; Piccart MJ; Cardoso F
Eur J Cancer; 2007 Mar; 43(4):725-35. PubMed ID: 17251007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
